StemCells, Inc. to Participate in the 3rd Annual Growth Capital Expo MicroCap Investor Conference in Las Vegas, NV
29 April 2016 - 1:46AM
StemCells, Inc. (Nasdaq:STEM) announced today that management will
make a presentation on the Company's programs, pipeline and
operations at the 3rd Annual Growth Capital Expo MicroCap Investor
Conference, held May 3 – 5, 2016 at Caesars Palace in Las Vegas,
NV. The Company will be presenting at 11:00 a.m. Pacific Daylight
Time on Wednesday, May 4.
A live webcast of the presentation will be
available through the Company's corporate website:
http://www.stemcellsinc.com. Interested parties are encouraged to
connect to the website at least 15 minutes prior to the
presentation to ensure adequate time for any software downloads
that may be necessary. In addition, you may directly access the
webcasts through the following link:
http://wsw.com/webcast/gce3/stem
A replay will also be accessible for 90 days
through the Company's website.
About StemCells, Inc.
StemCells, Inc. is currently engaged in clinical
development of its HuCNS-SC® platform technology (purified human
neural stem cells) as a potential treatment for chronic spinal cord
injury (SCI). The Company's Pathway Study, a Phase II
proof-of-concept trial in chronic cervical SCI is actively
enrolling at thirteen sites in the U.S. and Canada. Six-month
interim data for the first cohort of the Pathway Study showed the
first-ever clinical evidence of a treatment effect improving both
upper muscle strength and motor function following cellular
transplant in spinal cord injury. Top-line data from the Company's
earlier Phase I/II clinical trial in chronic thoracic SCI showed
measurable gains involving multiple sensory modalities and segments
in seven of twelve patients enrolled in the study, including the
conversion of two patients from the complete AIS-A spinal cord
injury to the incomplete AIS-B spinal cord injury. The Company has
also completed its Phase I/II clinical trial in geographic atrophy,
the most advanced form of dry age related macular degeneration.
Top-line results from this study show a positive safety profile and
favorable preliminary efficacy data. In a Phase I clinical trial in
Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in
children, the Company showed preliminary evidence of progressive
and durable donor-derived myelination by MRI. A Phase I study in
children with Batten’s disease showed that transplantation of the
cells into the brain was safe and resulted in long term survival of
the cells.
Further information about StemCells, Inc. is
available at http://www.stemcellsinc.com.
Apart from statements of historical fact, the
text of this press release constitutes forward-looking statements
within the meaning of the U.S. securities laws, and is subject to
the safe harbors created therein. These forward-looking statements
speak only as of the date of this news release. The Company does
not undertake to update any of these forward-looking statements to
reflect events or circumstances that occur after the date hereof.
Such statements reflect management's current views and are based on
certain assumptions that may or may not ultimately prove valid. The
Company's actual results may vary materially from those
contemplated in such forward-looking statements due to risks and
uncertainties to which the Company is subject, including those
described under the heading "Risk Factors" in the Company's Annual
Report on Form 10-K for the year ended December 31, 2015 and in its
subsequent reports on Forms 10-Q and 8-K.
CONTACT:
Greg Schiffman, Chief Financial Officer
StemCells, Inc.
(510) 456-4128
Lena Evans
Russo Partners
(212) 845-4262
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Apr 2024 to May 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From May 2023 to May 2024